Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
There is no TGA-registered BPC-157 product for therapeutic use in Australia, and as of June 2024 BPC-157 is a Schedule 4 (prescription-only) substance, meaning any legal supply must come through a doctors prescription via a compounding pharmacy
Chem Biol Interact 319:108984
Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumors and cellular schwannomas
The 2.5 mg dose is intended for treatment initiation only and is not considered therapeutically effective for maintenance
It differs fromPT-141 (Bremelanotide), a modified heptapeptide derivative with MC4R preference, and afamelanotide (Scenesse, FDA 2019), a linear tridecapeptide MC1R selective approved for erythropoietic protoporphyria
US$ 26.82
US$ 20.46
US$ 24.98
US$ 27.39
US$ 24.70
US$ 21.07
US$ 28.34
US$ 26.32
